Abstract
Immunotherapy has changed the standard treatment for lung cancer. While Immuno-Oncology (IO) agents may be better tolerated compared to conventional chemotherapy, immune related adverse events differ from those seen with traditional chemotherapy and potentially involve every organ system. Dermatologic, gastrointestinal, hepatic and endocrine toxicities typically predominate the adverse events profile of these agents. Severe autoimmune side effects may be experienced by patients treated with these new drugs.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
